A Booz & Company study titled "The Future of Heath Insurance" forecasts how health reform will shift the landscape for health plans, predicting they will emerge with specialized capabilities targeted to specific customer segments.
A Booz & Company study titled "The Future of Heath Insurance" forecasts how health reform will shift the landscape for health plans, predicting they will emerge with specialized capabilities targeted to specific customer segments.
The study found that most large and mid-sized employers will continue to offer traditional employer-based insurance, that healthcare reform will lead to a larger overall market for health insurance, and that 5 to 7 million employees will exit employee-sponsored health plans by 2016.
Those exit numbers may not be as alarming as they sound.
"One could imagine it's merely a shift in the status and not necessarily a shift from one insurer to another," says Gary Ahlquist, Booz & Company senior vice president. "In Massachusetts, for instance, when it brought up its connector, Blue Cross Blue Shield (BCBS) got at least its share of past business."
The study indicates that health plans will experience a gradual but steady erosion of their fully insured group business, as exchanges create a retail environment in which customers shop for healthcare plans in the same way that they currently shop for life insurance.
"Payers will have to figure out how to play a role in exchanges," says Ahlquist. " I think the payers' role will change to a broader one - a mass market or multi-segment role. In this case the biggest shift is coming at the small group, small business end of the spectrum that tends to be the traditional face of the BCBS system. They will perhaps be most affected by the change since that is the core of their business."
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
ICER Identifies 5 Drugs with Unsupported Price Increases
December 12th 2024The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz — with prices increases that are not supported by new clinical evidence, with a total of $815 million in added costs to U.S. payers in 2023.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen